🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 45256X103 (prev. 63016Q102 )
- Market Cap
- Large Cap
- IPO
- 7/28/2015 · $25.00/share
- Previous Symbol
- NK (changed 3/10/2021)
- Previous Name
- NantKwest, Inc.
Business: ImmunityBio, Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.
Notes: December 21, 2020 -- NantKwest and ImmunityBio entered into a merger agreement providing for the combination of the two companies to create a leading immunotherapy and cell therapy company focused on oncology and infectious disease. The combination will be implemented by means of a merger of a NantKwest subsidiary with and into ImmunityBio, resulting in ImmunityBio becoming a wholly-owned subsidiary of NantKwest. In connection with the closing of the merger, the combined company will assume the ImmunityBio name and shares of common stock of the combined company are expected to be listed on the NASDAQ Global Select Market under the symbol “IBRX”.
Company Contact
- CEO
- Richard Adcock
- CFO
- Sonja Nelson
- Headquarters
- 3530 John Hopkins Court, San Diego, CA 92121
- Phone
- 844-696-5235
- Investor Relations
- Sarah Singleton · 844-696-5235 · Investors@immunitybio.com